Literature DB >> 24398933

Effects of the PPAR-α agonist fenofibrate on acute and short-term consequences of brain ischemia.

Thavarak Ouk1, Sophie Gautier1, Maud Pétrault1, David Montaigne2, Xavier Maréchal3, Isabelle Masse1, Jean-Christophe Devedjian4, Dominique Deplanque1, Michèle Bastide1, Rémi Nevière3, Patrick Duriez1, Bart Staels5, Florence Pasquier6, Didier Leys7, Régis Bordet1.   

Abstract

In stroke, there is an imperative need to develop disease-modifying drugs able to (1) induce neuroprotection and vasculoprotection, (2) modulate recovery and brain plasticity, and (3) limit the short-term motor and cognitive consequences. We hypothesized that fenofibrate, a peroxisome proliferator-activated receptor-α (PPAR-α) agonist, could exert a beneficial effect on immediate and short-term poststroke consequences related to its pleiotropic mechanisms. Rats or mice were subjected to focal ischemia to determine the effects of acute treatment by fenofibrate on (i) motor and memory impairment, (2) both cerebral and vascular compartments, (3) inflammation, (4) neurogenesis, and (5) amyloid cascade. We show that fenofibrate administration results in both neuronal and vascular protection and prevents the short-term motor and cognitive poststroke consequences by interaction with several mechanisms. Modulation of PPAR-α generates beneficial effects in the immediate poststroke consequences by mechanisms involving the interactions between polynuclear neutrophils and the vessel wall, and microglial activation. Fenofibrate modulates mechanisms involved in neurorepair and amyloid cascade. Our results suggest that PPAR-α agonists could check the key points of a potential disease-modifying effect in stroke.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24398933      PMCID: PMC3948136          DOI: 10.1038/jcbfm.2013.233

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  34 in total

Review 1.  Neurovascular regulation in the normal brain and in Alzheimer's disease.

Authors:  Costantino Iadecola
Journal:  Nat Rev Neurosci       Date:  2004-05       Impact factor: 34.870

Review 2.  The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia.

Authors:  Costantino Iadecola
Journal:  Acta Neuropathol       Date:  2010-07-11       Impact factor: 17.088

3.  Characterization of acute adverse-effect profiles of selected antiepileptic drugs in the grip-strength test in mice.

Authors:  Anna Zadrozniak; Ewa Wojda; Aleksandra Wlaź; Jarogniew J Łuszczki
Journal:  Pharmacol Rep       Date:  2009 Jul-Aug       Impact factor: 3.024

4.  Delayed cerebrovascular protective effect of lipopolysaccharide in parallel to brain ischemic tolerance.

Authors:  Michèle Bastide; Patrick Gelé; Olivier Pétrault; Qian Pu; Audrey Caliez; Emmanuel Robin; Dominique Deplanque; Patrick Duriez; Régis Bordet
Journal:  J Cereb Blood Flow Metab       Date:  2003-04       Impact factor: 6.200

Review 5.  Consideration of the ischaemic basis and treatment of Alzheimer's disease.

Authors:  Ryszard Pluta; Marzena Ułamek; Mirosław Jabłoński
Journal:  Folia Neuropathol       Date:  2010       Impact factor: 2.038

6.  Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1.

Authors:  P Delerive; K De Bosscher; S Besnard; W Vanden Berghe; J M Peters; F J Gonzalez; J C Fruchart; A Tedgui; G Haegeman; B Staels
Journal:  J Biol Chem       Date:  1999-11-05       Impact factor: 5.157

7.  Increased superoxide and vascular dysfunction in CuZnSOD-deficient mice.

Authors:  Sean P Didion; Michael J Ryan; Lisa A Didion; Pamela E Fegan; Curt D Sigmund; Frank M Faraci
Journal:  Circ Res       Date:  2002-11-15       Impact factor: 17.367

Review 8.  Alzheimer lesions after ischemia-reperfusion brain injury.

Authors:  Ryszard Pluta
Journal:  Folia Neuropathol       Date:  2004       Impact factor: 2.038

Review 9.  Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors.

Authors:  Philippe Gervois; Jean-Charles Fruchart; Bart Staels
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2007-02

10.  The Nuclear Receptor PPARgamma as a Therapeutic Target for Cerebrovascular and Brain Dysfunction in Alzheimer's Disease.

Authors:  Nektaria Nicolakakis; Edith Hamel
Journal:  Front Aging Neurosci       Date:  2010-05-21       Impact factor: 5.750

View more
  22 in total

Review 1.  Sex differences in the immune response to experimental stroke: Implications for translational research.

Authors:  Abby L Dotson; Halina Offner
Journal:  J Neurosci Res       Date:  2017-01-02       Impact factor: 4.164

2.  Oral administration of a novel lipophilic PPARδ agonist is not neuroprotective after rodent cerebral ischemia.

Authors:  Samuel Knauss; Matthias Endres; Florian Blaschke; Claudia Hindinger; Alexander Kunz
Journal:  J Cereb Blood Flow Metab       Date:  2017-11-21       Impact factor: 6.200

3.  Antidepressant-like effects of fenofibrate in mice via the hippocampal brain-derived neurotrophic factor signalling pathway.

Authors:  Bo Jiang; Ying-Jie Wang; Hao Wang; Lu Song; Chao Huang; Qing Zhu; Feng Wu; Wei Zhang
Journal:  Br J Pharmacol       Date:  2016-12-09       Impact factor: 8.739

4.  Pterostilbene ameliorates intracerebroventricular streptozotocin induced memory decline in rats.

Authors:  Bhagyashree Naik; Abhijit Nirwane; Anuradha Majumdar
Journal:  Cogn Neurodyn       Date:  2016-09-30       Impact factor: 5.082

Review 5.  Is fenofibrate a reasonable treatment for diabetic microvascular disease?

Authors:  Rafael Simó; Olga Simó-Servat; Cristina Hernández
Journal:  Curr Diab Rep       Date:  2015-05       Impact factor: 4.810

6.  12/15-Lipoxygenase metabolites of arachidonic acid activate PPARγ: a possible neuroprotective effect in ischemic brain.

Authors:  Li Sun; Yan-Wei Xu; Jing Han; Hao Liang; Ning Wang; Yan Cheng
Journal:  J Lipid Res       Date:  2015-01-20       Impact factor: 5.922

7.  Early treatment with atorvastatin exerts parenchymal and vascular protective effects in experimental cerebral ischaemia.

Authors:  C Potey; T Ouk; O Petrault; M Petrault; V Berezowski; J Salleron; R Bordet; S Gautier
Journal:  Br J Pharmacol       Date:  2015-10-06       Impact factor: 8.739

8.  Fenofibrate reduces intestinal damage and improves intestinal recovery following intestinal ischemia-reperfusion injury in a rat.

Authors:  I Sukhotnik; N Nissimov; Y Ben Shahar; D Moati; N Bitterman; Y Pollak; D Berkowitz; A G Coran; A Bitterman
Journal:  Pediatr Surg Int       Date:  2016-09-20       Impact factor: 1.827

9.  PPARα Agonist Fenofibrate Ameliorates Learning and Memory Deficits in Rats Following Global Cerebral Ischemia.

Authors:  Ai-Guo Xuan; Yan Chen; Da-Hong Long; Meng Zhang; Wei-Dong Ji; Wen-Juan Zhang; Ji-Hong Liu; Le-Peng Hong; Xiao-Song He; Wen-Liang Chen
Journal:  Mol Neurobiol       Date:  2014-09-23       Impact factor: 5.590

10.  Peroxisomal biogenesis in ischemic brain.

Authors:  Jennifer M Young; Jonathan W Nelson; Jian Cheng; Wenri Zhang; Sarah Mader; Catherine M Davis; Richard S Morrison; Nabil J Alkayed
Journal:  Antioxid Redox Signal       Date:  2015-01-10       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.